Table 3 Positivity for YB-1/p18 detection in human serum samples of patients with different malignant disorders
n | YB-1/p18 positivity n/N (%) | |
|---|---|---|
All patients | 151 | 117/151 (77.5) |
Male | 84 | 67/84 (79.8) |
Female | 67 | 50/67 (74.6) |
Malignancy | ||
Group I: lung cancer | 37 | 32/37 (86.5) |
Adeno | 15 | 12/15 (80) |
Small cell | 10 | 9/10 (90) |
Squamous | 10 | 9/10 (90) |
Non small cell | 2 | 2/2 (100) |
Group II: breast cancer | 10 | 7/10 (70) |
Ductal | 9 | 6/9 (66.7) |
Lobular | 1 | 1/1 (100) |
Group III: gastrointestinal | 16 | 10/16 (62.5) |
Stomach cancer | 3 | 2/3 (66.7) |
Colorectal cancer | 7 | 4/7 (57.1) |
Other | 6 | 4/6 (66.7) |
Group IV: hematological | 62 | 42/62 (67.7) |
Acute myeloid leukemia | 7 | 4/7 (57.1) |
Chronic myelogenous leukemia | 2 | 1/2 (50) |
Hodgkin’s lymphoma | 5 | 4/5 (85.7) |
Non-Hodgkin’s lymphoma | 13 | 11/13 (84.6) |
Other lymphoma | 7 | 6/7 (85.7) |
Multiple myeloma | 13 | 10/13 (77) |
Idiopathic thrombocytopenia | 5 | 4/5 (76.9) |
Myelodysplastic syndrome | 10 | 2/10 (20) |
Group V: urogenital cancers | 8 | 8/8 (100) |
Ovarian cancer | 2 | 2/2 (100) |
Testicular cancer | 2 | 2/2 (100) |
Prostate cancer | 1 | 1/1 (100) |
Urinary tract cancer | 3 | 3/3 (100) |
Group VI: CUP | 5 | 5/5 (100) |
Group VII: other solid tumors | 13 | 13/13 (100) |